As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

Sanofi and Regeneron acknowledged that testing their inflammatory disease blockbuster Dupixent in chronic obstructive pulmonary disease (COPD) was likely to be high-risk when they launched phase 3 ...

Regeneron initiated a quarterly dividend per share that looks somewhat attractive. Despite some recent issues, the biotech ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what makes REGN stock a compelling buy.

The fact that the US Food and Drug Administration has approved using Dupixent to treat COPD positions Regeneron to generate billions of dollars in annual sales. Dupixent has the potential to ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

"The COPD PRS captures only a small proportion of ... Northpond Laboratories, Regeneron, Sanofi, and Apogee. Labaki disclosed no relevant conflicts of interest. Source Reference: Zhang J, et ...